𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Midkine as a prognostic marker for gastrointestinal stromal tumors

✍ Scribed by Jussuf T. Kaifi; Henning C. Fiegel; Svanheidur L. Rafnsdottir; Kuniaki Aridome; Paulus G. Schurr; Uta Reichelt; Robin Wachowiak; Helge Kleinhans; Emre F. Yekebas; Oliver Mann; Keiko Ichihara-Tanaka; Takashi Muramatsu; Dietrich Kluth; Tim Strate; Jakob R. Izbicki

Book ID
106123653
Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
313 KB
Volume
133
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Hepatoma-derived growth factor is a nove
Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors
✍ Kuo-Chin Chang; Ming-Hong Tai; Jui-Wei Lin; Chih-Chi Wang; Chao-Cheng Huang; Cha πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 335 KB

## Abstract Proliferating activity as mitotic count is generally accepted as a major prognostic indicator for gastrointestinal stromal tumors (GISTs). Hepatoma‐derived growth factor (HDGF) is a novel growth factor and elevated in several types of cancer. Our study was designed to elucidate the expr

Imatinib as adjuvant therapy for gastroi
Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review
✍ Munira Essat; Katy Cooper πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 266 KB πŸ‘ 1 views

## Abstract The high risk of recurrence in resected gastrointestinal stromal tumor (GIST) highlights the need for effective adjuvant treatment. This review evaluates the clinical efficacy and safety of imatinib for adjuvant treatment of localized KIT (CD117)‐positive resected GIST. Relevant studies